Osteocalcin
Also known as: bone Gla protein, BGP, osteocalcin peptide, uncarboxylated osteocalcin, ucOC
Endogenous 49-amino acid bone-derived peptide hormone; osteoblast-secreted osteokine; vitamin K-dependent calcium-binding protein; systemic metabolic regulator
What it is
Osteocalcin is a bone-derived hormone of growing interest among athletes, biohackers, and people managing metabolic health. The body naturally produces it during bone remodeling; circulating levels rise with exercise and decline with age. Researchers are investigating it for roles in blood sugar control, testosterone support, muscle function, and cognitive performance.
The scientific side
osteocalcin (OCN) is a 49-amino acid peptide secreted exclusively by osteoblasts during bone matrix synthesis, with its biological activity tightly regulated by vitamin K-dependent gamma-carboxylation of three glutamic acid residues. The fully carboxylated form (cOCN) binds with high affinity to hydroxyapatite in bone matrix and has limited endocrine activity. Under physiological conditions including bone resorption, mechanical loading, and acidification of the bone resorption lacunae, cOCN undergoes decarboxylation to yield the undercarboxylated form (ucOCN), which is released into circulation and exerts hormone-like effects across multiple organ systems (PMID 17693256; PMID 41977179). The primary signaling receptor for ucOCN is GPRC6A, a G protein-coupled receptor expressed in pancreatic beta-cells, skeletal muscle, testicular Leydig cells, neurons, adipose tissue, and the vascular endothelium. Binding of ucOCN to GPRC6A on pancreatic beta-cells stimulates insulin secretion and promotes beta-cell proliferation via cyclin D1-dependent pathways, improving glucose homeostasis (PMID 24009262; PMID 21550430). In skeletal muscle, ucOCN signaling through GPRC6A increases glucose uptake, supports mitochondrial function, and suppresses TNF-alpha-driven inflammatory signaling in myoblasts (PMID 35702666; PMID 24554534). An exercise-osteocalcin axis has been established: acute high-intensity exercise acutely elevates both total OCN and ucOCN in serum in a sex-independent manner, consistent with mechanical strain triggering bone resorption and ucOCN release, which then feeds back to support muscle energy demands during exercise (PMID 33338665). In male reproductive endocrinology, ucOCN binds GPRC6A on Leydig cells, activating PKA-MAPK/ERK-CREB signaling to increase steroidogenic gene expression and testosterone biosynthesis (PMID 41439957; PMID 21333348). In the central nervous system, ucOCN crosses the blood-brain barrier and modulates serotonin, dopamine, and GABA neurotransmitter systems; knockout mouse models demonstrate severe deficits in spatial learning, memory, and increased anxiety-like behavior in the absence of osteocalcin (PMID 29376523; PMID 42177196). In adipose tissue, ucOCN reduces inflammation via NF-kB pathway suppression and enhances insulin signaling and GLUT4 expression, contributing to improvements in insulin resistance in obesity models (PMID 29183784). Circulating osteocalcin levels decline progressively from adolescence through midlife and further into older age, a pattern conserved across species, suggesting declining ucOCN contributes to age-associated metabolic deterioration and cognitive decline (PMID 29376523; PMID 42539930).
Class: Endogenous 49-amino acid bone-derived peptide hormone; osteoblast-secreted osteokine; vitamin K-dependent calcium-binding protein; systemic metabolic regulator
Administration & storage
- Administration
- Subcutaneous injection (used in all published rodent studies)Intraperitoneal injection (used in some acute mouse dosing protocols)
- Storage
- Lyophilized research-grade osteocalcin peptide is generally stable at -20°C to -80°C. Once reconstituted, solutions should be aliquoted, stored at -20°C, and used within manufacturer-recommended windows (typically days to weeks). Osteocalcin is subject to proteolytic degradation and should not be subjected to repeated freeze-thaw cycles. These conditions apply to research reagents only; no pharmaceutical-grade product for human use exists.
- Cautions
- No human safety data exist for exogenous osteocalcin administration; no Phase I dose-escalation trial has been completed and published.,The GPRC6A receptor mediates osteocalcin signaling in multiple tissues including pancreas, gonads, and CNS; unpredictable pleiotropic effects from supraphysiological dosing cannot be excluded.,Osteocalcin has a short circulating half-life; the pharmacokinetics of exogenous administration in humans are unknown.,Self-sourced peptides carry risks of impurity, incorrect concentration, contamination, and unknown immunogenicity.,Unintended modulation of parathyroid cell function via GPRC6A has been documented in vitro, including modulation of PTH secretion and cell survival signaling (PMID 37065733), with unknown clinical implications.,Potential for dysregulation of testosterone biosynthesis in males; supraphysiological ucOCN stimulation of Leydig cells could theoretically disrupt the feedback balance of the HPG axis (PMID 41439957).
Legal & regulatory status
Osteocalcin has no FDA-approved drug formulation for therapeutic use in humans as of 2026. It is not cleared as a drug, biologic, or dietary supplement ingredient by the FDA. Serum osteocalcin and undercarboxylated…
Osteocalcin is not currently listed on the WADA Prohibited List. It is an endogenous peptide produced naturally during bone remodeling and rises acutely with exercise; this physiological release pattern makes it…
Osteocalcin is not approved by Health Canada as a drug or natural health product for human therapeutic use. No Health Canada Drug Product Database (DPD) entry or Natural and Non-prescription Health Products Directorate…
What it's studied for
- Glucose homeostasis and type 2 diabetes prevention Animal RCT / Human observational
- Skeletal muscle mass, strength, and body composition Systematic review / Human observational
- Male reproductive function and testosterone biosynthesis Animal mechanistic / Human cross-sectional
- Cognitive function and neuroprotection Animal mechanistic / Early human observational
- Insulin resistance and metabolic syndrome in obesity Animal RCT / Human observational
- Osteoarthritis cartilage protection via GPRC6A/HIF-1alpha pathway Preclinical mechanistic
- Aerobic exercise performance and endurance capacity Animal mechanistic / Human observational
Safety signals
- No human clinical safety data — complete absence of Phase I human trials
- Pleiotropic GPRC6A signaling — potential unintended endocrine effects across multiple organ systems
- Parathyroid cell function modulation — osteocalcin alters PTH secretion and anti-apoptotic signaling in parathyroid adenoma cells
- Possible paradoxical reduction in insulin-stimulated glucose uptake at high concentrations in myotubes
- Endocrine disruption of the hypothalamic-pituitary-gonadal (HPG) axis — theoretical risk with supraphysiological ucOCN exposure
- Altered glucose homeostasis risk — insulin secretagogue and insulin sensitizer effects could theoretically cause hypoglycemia
- Unknown immunogenicity profile for recombinant or synthetic osteocalcin in humans
All studies (14)
Frequently asked
Does taking osteocalcin boost testosterone?
Animal studies and cell culture experiments support a mechanism by which the undercarboxylated form of osteocalcin (ucOCN) binds to GPRC6A receptors on testicular Leydig cells and stimulates testosterone synthesis through a PKA-ERK-CREB signaling cascade. Human cross-sectional data show positive correlations between serum ucOCN and testosterone levels in infertile and eugonadal men. However, no human clinical trial has tested exogenous osteocalcin administration for testosterone support, and no dose, formulation, or safety profile has been established in humans. These remain preliminary mechanistic findings.
Does exercise increase osteocalcin levels?
Yes. Multiple human studies confirm that acute high-intensity exercise significantly and transiently elevates both total osteocalcin and undercarboxylated osteocalcin (ucOCN) in serum. This increase occurs similarly in males and females. The proposed mechanism is exercise-induced mechanical loading and bone resorption releasing osteocalcin from bone matrix into circulation. This exercise-induced rise is transient; several weeks of HIIT training did not produce lasting elevations in resting osteocalcin levels in one human cohort study. High-impact eccentric exercise has also been documented to acutely increase serum osteocalcin.
Can osteocalcin improve memory or prevent cognitive decline?
Animal research shows that osteocalcin is necessary for normal brain development and cognitive function in mice, and that circulating ucOCN can cross the blood-brain barrier to modulate neurotransmitter systems linked to learning and memory. In aging and ovarian insufficiency mouse models, declining ucOCN correlated with worsening cognitive outcomes, and restoring osteocalcin improved them. In older humans with memory concerns, higher levels of bone-related biomarkers including osteocalcin forms were associated with slower cognitive decline over 18 months. These findings are preliminary; no human interventional trial has tested osteocalcin supplementation for cognitive outcomes.
Is osteocalcin the same as a bone turnover marker?
Osteocalcin is used clinically as a serum marker of osteoblast activity and bone formation rate. In this diagnostic context, it is measured to monitor bone turnover in osteoporosis management, response to anti-resorptive therapy, and metabolic bone disease. However, osteocalcin is also a functional hormone with systemic endocrine effects on metabolism, reproduction, and the nervous system — particularly in its undercarboxylated (ucOC) form. The distinction between osteocalcin as a diagnostic marker and as a potential therapeutic target is important when interpreting both laboratory results and research literature.
Where can I buy osteocalcin peptide, and is it legal?
Osteocalcin is not approved by the FDA, Health Canada, or any major regulatory authority as a pharmaceutical drug for human use. It is available as a research-grade biochemical reagent from scientific suppliers but these products are not manufactured to pharmaceutical standards and are not intended or labeled for human administration. In most jurisdictions, purchasing research peptides for personal injection occupies a legal grey area distinct from approved medications. WADA has not listed osteocalcin on its Prohibited List. This website does not endorse, facilitate, or recommend the purchase or self-administration of osteocalcin.